公开(公告)号：EP4436959A1

公开(公告)日：2024-10-02

申请号：EP22897852.4

申请日：2022-11-23

申请人： Allorion Therapeutics Inc.

发明人： CHENG, Dai ,  DING, Qiang ,  ZHANG, Tao

IPC分类号： C07D239/48 ,  C07D405/12 ,  A61K31/505 ,  A61P35/00

CPC分类号： C07D239/48 ,  A61P35/00 ,  Y02P20/55 ,  C07D239/47 ,  C07D405/12 ,  C07D401/14 ,  C07D401/12 ,  C07D405/14 ,  C07D239/42 ,  C07D401/04

公开(公告)号：EP3957627B1

公开(公告)日：2024-06-19

申请号：EP21196697.3

申请日：2016-04-22

IPC分类号： C07D213/69 ,  A61K31/4412 ,  A61K31/505 ,  A61K31/506 ,  A61K31/53 ,  A61K31/5377 ,  A61P1/02 ,  A61P1/04 ,  A61P1/16 ,  A61P1/18 ,  A61P3/10 ,  A61P9/10 ,  A61P11/00 ,  A61P11/06 ,  A61P11/08 ,  A61P13/00 ,  A61P13/08 ,  A61P13/10 ,  A61P13/12 ,  A61P17/02

CPC分类号： C07D403/12 ,  A61K31/4412 ,  A61K31/505 ,  A61K31/506 ,  A61K31/53 ,  A61K31/5377 ,  C07D213/74 ,  C07D401/06 ,  C07D401/12 ,  C07D405/12 ,  C07D239/47 ,  C07D239/48 ,  C07D409/06 ,  C07D239/54 ,  C07D409/12 ,  C07D239/60 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D253/06 ,  C07D487/04 ,  C07D498/04 ,  C07D213/69 ,  C07D239/52 ,  C07D239/545 ,  C07D253/075 ,  A61P1/02 ,  A61P1/04 ,  A61P1/16 ,  A61P1/18 ,  A61P11/00 ,  A61P11/06 ,  A61P11/08 ,  A61P13/00 ,  A61P13/08 ,  A61P13/10 ,  A61P13/12 ,  A61P17/02 ,  A61P17/04 ,  A61P17/06 ,  A61P19/00 ,  A61P19/02 ,  A61P19/06 ,  A61P19/08 ,  A61P19/10 ,  A61P21/02 ,  A61P25/00 ,  A61P25/02 ,  A61P25/04 ,  A61P25/06 ,  A61P25/08 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18 ,  A61P25/20 ,  A61P25/24 ,  A61P25/28 ,  A61P25/30 ,  A61P25/34 ,  A61P25/36 ,  A61P27/00 ,  A61P27/02 ,  A61P29/00 ,  A61P29/02 ,  A61P31/04 ,  A61P35/00 ,  A61P35/02 ,  A61P35/04 ,  A61P37/06 ,  A61P37/08 ,  A61P43/00 ,  A61P9/10 ,  A61P3/10

公开(公告)号：EP4382514A1

公开(公告)日：2024-06-12

申请号：EP22853399.8

申请日：2022-08-01

申请人： Korea Research Institute of Chemical Technology ,  Industry-Academic Cooperation Foundation, Yonsei University

发明人： LEE, Kwangho ,  DUGGIRALA, Krishna Babu ,  CHOI, Gil Don ,  CHAE, Chong Hak ,  JUNG, Myoung Eun ,  LEE, Yujin ,  CHO, Byoung Chul

IPC分类号： C07D239/48 ,  A61K31/505 ,  A61K31/5377 ,  A61K31/54 ,  A61K45/06 ,  A61P35/00 ,  C07D403/12 ,  C07D401/12 ,  C07D401/14 ,  C07D417/12

CPC分类号： A61K31/505 ,  A61K31/5377 ,  A61K31/54 ,  A61K45/06 ,  A61P35/00 ,  C07D239/48 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D417/12

摘要： The present invention relates to a pyrimidine derivative, a method for preparing same, and a pharmaceutical composition for preventing or treating cancer comprising same as an active ingredient. The pyrimidine derivative of the present invention exhibits a high inhibitory ability against EGFR mutation and HER2 mutation, and thus can be effectively used in treatment of cancer in which EGFR mutation and HER2 mutation have occurred.

公开(公告)号：EP4366724A2

公开(公告)日：2024-05-15

申请号：EP22838517.5

申请日：2022-07-11

申请人： CZ Biohub SF, LLC ,  The Board and Trustees of the Leland Stanford Junior University

发明人： ALFORD, Vincent ,  SMITH, Mark ,  CLARKE, Michael, F. ,  GURJAR, Jitendra ,  KUO, Angera, Hsiao-Chi

IPC分类号： A61K31/33 ,  A61K31/435 ,  A61K31/395 ,  A61K31/4545

CPC分类号： C07D401/12 ,  A61K45/06 ,  C07D401/14 ,  C07D213/74 ,  C07D239/42 ,  C07D401/06 ,  C07D401/04 ,  C07D403/12 ,  C07D401/10 ,  C07D401/08 ,  C07D239/48 ,  C07D405/14

公开(公告)号：EP4356975A2

公开(公告)日：2024-04-24

申请号：EP24161138.3

申请日：2019-01-28

申请人： DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD.

发明人： LI, Zhengtao ,  ZOU, Hao ,  ZHU, Wei ,  SHEN, Changmao ,  WANG, Rumin ,  LIU, Wengeng ,  CHEN, Xiang ,  TSUI, Honchung ,  YANG, Zhenfan ,  ZHANG, Xiaolin

IPC分类号： A61P37/02

CPC分类号： A61K31/505 ,  A61K31/506 ,  A61P9/02 ,  A61P17/00 ,  A61P35/02 ,  A61P37/02 ,  C07D239/48 ,  A61P35/00 ,  C07D403/12 ,  C07D405/12 ,  C07D251/18 ,  C07D487/04 ,  C07D401/12 ,  A61K31/53 ,  A61K45/06 ,  C07D413/12 ,  C07D403/14 ,  C07C53/02

摘要： Disclosed are compounds inhibiting ErbBs (e. g., EGFR or Her 2), especially mutant forms of ErbBs, and BTK, pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds. The compound and the pharmaceutical composition can effectively treat ErbBs (especially mutant forms of ErbBs) or BTK associated diseases, including cancer.

公开(公告)号：EP3392245A1

公开(公告)日：2018-10-24

申请号：EP16874860.6

申请日：2016-12-15

申请人： Precedo Pharmaceuticals Co., Ltd.

发明人： LIU, Jing ,  LIU, Qingsong ,  JIANG, Taoshan ,  WANG, Aoli ,  WU, Jiaxin ,  WU, Hong ,  QI, Ziping ,  CHEN, Yongfei ,  ZOU, Fengming ,  WANG, Wenchao ,  ZHAO, Zheng ,  WANG, Li ,  WANG, Beilei

IPC分类号： C07D401/12 ,  C07D239/48 ,  C07D403/12 ,  C07D239/47 ,  C07D409/12 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/551 ,  A61P35/00 ,  A61P35/02

CPC分类号： A61K31/506 ,  A61K31/5377 ,  A61K31/551 ,  C07D239/47 ,  C07D239/48 ,  C07D401/12 ,  C07D403/12 ,  C07D409/12 ,  Y02P20/55

摘要： The present application provides a compound of formula I, which is a EGFR and ALK dual inhibitor and can be used alone or in combination with other therapeutic agents to treat diseases such as non-small cell lung cancer. The compounds of the present application are useful in the treatment of diseases carrying the EGFR wild-type gene, or carrying the EGFR T790M mutant gene and/or the EGFR L858R mutant gene and/or the EGFR delE746_A750 mutant gene, or in the treatment of diseases carrying the ALK wild-type gene, ALK F1174L mutant gene and/or ALK F1196M gene and/or EML4-ALK mutant gene and/or NPM-ALK mutant gene, and can be used in the first-line treatment of anaplastic lymphoma kinase (ALK) positive late-stage non-small cell Lung cancer.

公开(公告)号：EP3122731B1

公开(公告)日：2018-10-10

申请号：EP15713431.3

申请日：2015-03-25

申请人： Elanco Tiergesundheit AG

发明人： GAUVRY, Noelle ,  TAHTAOUI, Chouaib ,  FURET, Pascal ,  DUCRAY, Pierre

IPC分类号： C07D239/46 ,  C07D471/04 ,  C07D471/14 ,  C07D473/34 ,  C07D487/04 ,  C07D495/04 ,  A61K31/44 ,  A61K31/50 ,  A61K31/505 ,  A61K31/52

CPC分类号： C07D471/14 ,  C07D239/42 ,  C07D239/46 ,  C07D239/48 ,  C07D471/04 ,  C07D473/34 ,  C07D487/04 ,  C07D495/04

摘要： The invention relates to a compound of formula wherein the variables have the meaning as indicated in the claims; in free form and in salt form; and optionally the enantiomers and geometrical isomers thereof. The compounds of formula (I) are useful as therapeutic agent for organ transplants, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, inflammatory bowel diseases, Crohn's disease, Alzheimer's disease, leukemia, osteoarthritis, control of pruritus, chronic respiratory disease or keratoconjunctivitis in mammals.

公开(公告)号：EP2825160B1

公开(公告)日：2018-10-03

申请号：EP13711103.5

申请日：2013-03-13

申请人： University Court of The University of Dundee ,  DANA-FARBER CANCER INSTITUTE, INC.

发明人： COHEN, Philip ,  CLARK, Kristopher ,  CHOI, Hwan, Geun ,  GRAY, Nathanael

IPC分类号： A61K31/00 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5377 ,  A61P29/00

CPC分类号： C07D239/48 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5377 ,  C07D403/12 ,  C07D413/12 ,  C07D487/04

摘要： The present invention relates to the discovery that salt inducible kinases (SIKs) suppress the formation of anti-inflammatory molecules such as IL-10, which are important for the resolution of inflammation and identifies SIK inhibitors that may be used to treat disorders associated with undesirable inflammation, such as inflammatory bowel disease and/or autoimmune disorders.

公开(公告)号：EP2361248B1

公开(公告)日：2018-09-19

申请号：EP09771102.2

申请日：2009-06-26

申请人： Celgene CAR LLC

发明人： KLUGE, Arthur, F. ,  PETTER, Russell, C. ,  TESTER, Richland, Wayne ,  QIAO, Lixin ,  NIU, Deqiang ,  WESTLIN, William, Frederick ,  SINGH, Juswinder ,  MAZDIYASNI, Hormoz

IPC分类号： C07D239/47 ,  C07D239/48 ,  C07D401/14 ,  C07D403/12 ,  C07D407/12 ,  C07D413/12 ,  C07D413/14 ,  C07D471/04 ,  C07D487/04 ,  C07D487/18 ,  A61K31/505 ,  A61K31/506 ,  A61P29/00 ,  A61P35/00 ,  A61P37/00

CPC分类号： A61K31/505 ,  A61K31/506 ,  A61K31/5377 ,  C07D239/47 ,  C07D239/48 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D407/12 ,  C07D413/12 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D487/18

摘要： The present invention provides 2,4-disubstituted pyrimidine compounds useful as kinase inhibitors, pharmaceutically acceptable compositions thereof, and methods of using the same. In some embodiments, the present invention provides a compound of formula I-b: wherein each of Ring A, Ring B, W1, W2, Ry, Rv, Rx, m, p, and R1 is described herein.

公开(公告)号：EP3368530A1

公开(公告)日：2018-09-05

申请号：EP16794164.0

申请日：2016-10-28

申请人： Effector Therapeutics Inc.

发明人： SPRENGELER, Paul, A. ,  REICH, Siegfried, H. ,  ERNST, Justin, T. ,  WEBBER, Stephen, E. ,  SHAGHAFI, Mike ,  MURPHY, Douglas ,  TRAN, Chinh

IPC分类号： C07D403/12 ,  C07D401/12 ,  C07D403/14 ,  C07D239/42 ,  C07D239/49 ,  C07D409/12 ,  C07D417/12 ,  C07D487/04 ,  A61K31/52 ,  A61K31/506 ,  A61K31/505 ,  A61P35/00

CPC分类号： C07D498/04 ,  C07D239/42 ,  C07D239/48 ,  C07D239/49 ,  C07D401/12 ,  C07D403/12 ,  C07D403/14 ,  C07D409/12 ,  C07D409/14 ,  C07D417/12 ,  C07D471/04 ,  C07D471/10 ,  C07D473/34 ,  C07D487/04 ,  C07D491/107

摘要： For Formula I compounds A1, A2, A3, A4, A5, W1, Y, R1, R2, R3, R4, R5, R6a, R6b, R7, R8, R8a, R8b, R9, R9a, R9b, and R10 and subscript “n” are as defined in the specification. The inventive Formula I compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.